Liver Transplantation With Two-stage Liver Resection in Unresectable Liver Cancer , Metastases or Emd-stage Liver Disease (LTLR-LC)

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorRenJi Hospital

About this trial

Colon cancer and primary liver cancer are common malignant tumors with low survival rate worldwide, and unresectable primary liver cancer and colon cancer liver metastases have worse prognosis. End-stage liver disease is equated with advanced liver disease, liver failure and decompensated cirrhosis because they are generally irreversible. Liver transplantation is a treatment option for the above-mentioned patients and is expected to improve the prognosis of the patients, but the biggest problem faced by such patients is the shortage of donor livers. Recently, a new surgical modality, resection and partial liver segment 2-3 transplantation with delayed total hepatectomy (RAPID), can greatly alleviate these problems.Based on clinical surgical experience, our center proposes and designs a clinical study of adjuvant liver transplantation combined with two-stage hepatectomy in the treatment of patients with unresectable primary liver cancer, colorectal cancer liver metastases, or end-stage liver disease. By improvement of RAPID operation, the safety and efficacy of this treatment method in patients with those disease were evaluated.

Eligibility criteria

Qualifiers

aged 18-75 years;

patients with unresectable primary hepatocellular carcinoma or colorectal cancer with liver metastases who also meet the following criteria: tumor shrinkage (still unresectable) or no significant progression after a first-line chemotherapy regimen of 6-8 weeks; no other abdominal metastases or 1-3 resectable pulmonary metastases;

patients with end-stage liver disease;

preoperative Child classification of A or B, able to tolerate the subsequent surgical program

Disqualifiers

Extrahepatic tumor burden (except for resectable lung metastases) and/or macrovascular tumor infiltration

Tumor progression during chemotherapy or important comorbidities that affect surgery

Uncorrectable cardiopulmonary disease with high surgical risk

Anatomical abnormalities that preclude liver transplantation

Trial design

Treatments tested in this trial

  • assisted liver transplantation combined with two-stage hepatectomy

Treatment groups

30 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

RenJi Hospital

Lead sponsor

The Affiliated Hospital of Qingdao University

Collaborator

The First Affiliated Hospital of Zhengzhou University

Collaborator